{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:40:12Z","timestamp":1792104012386,"version":"4.4.0"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T00:00:00Z","timestamp":1392940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hyper\u2010<jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> is widely used to treat acute lymphoblastic leukemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>) and aggressive lymphomas. This multicenter, population\u2010based study assessed the efficacy of Hyper\u2010<jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> as first\u2010line therapy in patients with T\u2010cell <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> (T\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Between October 2002 and September 2006, 24 patients were diagnosed with T\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> in Sweden; 19 were eligible for treatment with the protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 32\u00a0yr (range 18\u201372\u00a0yr). Complete remission (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) was obtained in 17 of 19 (89%) patients, and the treatment was relatively well tolerated. Allogeneic stem cell transplantation (<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) was recommended in high\u2010risk disease and was performed in four patients upfront. Two\u2010 and 5\u2010yr leukemia\u2010free survivals (<jats:styled-content style=\"fixed-case\">LFS<\/jats:styled-content>) in 17 patients with <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> achievement were identical, at 29% (95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>]: 8\u201351). Two\u2010 and 5\u2010yr overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) in whole cohort was 63% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 42\u201385) and 47% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 26\u201369), respectively. The 5\u2010yr <jats:styled-content style=\"fixed-case\">LFS<\/jats:styled-content> for 15 patients who did not receive allogeneic <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> upfront were 20% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0\u201340), although 14 of 15 completed the protocol (eight cycles). Relapse occurred in 2 of 4 upfront\u2010transplanted patients and in 12 of 15 patients treated with chemotherapy alone, six of whom received allogeneic <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>2. Age \u226535\u00a0yr influenced OS negatively in univariate analysis (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 5.1, 95% CI: 1.55\u201316.7).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hyper\u2010<jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content> treatment resulted in a high <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> rate and appeared safe, but it showed poor efficacy at preventing relapse. Therefore, this treatment is no longer recommended for adults with T\u2010<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>weden.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12269","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T11:26:53Z","timestamp":1390217213000},"page":"377-381","source":"Crossref","is-referenced-by-count":33,"title":["High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper\u2010<scp>CVAD<\/scp> chemotherapy in <scp>S<\/scp>weden"],"prefix":"10.1111","volume":"92","author":[{"given":"Piotr","family":"Kozlowski","sequence":"first","affiliation":[{"name":"Hematology Section Department of Medicine \u00d6rebro University Hospital \u00d6rebro Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"\u00c5str\u00f6m","sequence":"additional","affiliation":[{"name":"Hematology Section Department of Medicine \u00d6rebro University Hospital \u00d6rebro Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ahlberg","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital of Link\u00f6ping Link\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Bernell","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Huleg\u00e5rdh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Coagulation Sahlgrenska University G\u00f6teborg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"H\u00e4gglund","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Hematology Sk\u00e5ne University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Markuszewska\u2010Kuczymska","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer Center University Hospital Ume\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Tomaszewska\u2010Toporska","sequence":"additional","affiliation":[{"name":"Department of Hematology Sk\u00e5ne University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Smedmyr","sequence":"additional","affiliation":[{"name":"Department of Hematology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose\u2010Marie","family":"Amini","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Hallb\u00f6\u00f6k","sequence":"additional","affiliation":[{"name":"Department of Hematology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Swedish Adult ALL Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231217"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03685.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-272724"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.84"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.057851"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.07.011"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12088"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2011.n.007"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32834bb854"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12097"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12269","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T08:59:47Z","timestamp":1695459587000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,21]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/ejh.12269"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12269","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,21]]}}}